Clinical Trials

Adalimumab in psoriasis: The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL)

Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here